Ipamorelin: Research Background and Overview

Ipamorelin is a synthetic pentapeptide first described in the late 1990s as a growth hormone secretagogue (GHS). It appears in the research literature primarily as a pharmacological tool for probing the growth hormone secretagogue receptor and, later, as an investigational candidate in a small number of clinical programs. It has never been approved as a drug in any jurisdiction.

This page is a reference summary of what the published literature reports about the molecule. It is written for a research audience and describes findings in laboratory and clinical research contexts only. It contains no protocols, no administration guidance, and no claims about outcomes in humans outside of what published trials measured.

What the molecule is

Ipamorelin (development code NNC 26-0161) is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Its molecular formula is C₃₈H₄₉N₉O₅, with a molar mass of approximately 711.9 g/mol, and it carries CAS registry number 170851-70-4.

Several structural features place it outside the class of ordinary linear peptides:

• Non-proteinogenic residues. Aib (2-aminoisobutyric acid) and D-2-naphthylalanine are not among the twenty standard amino acids. Aib in particular constrains backbone conformation.
• D-amino acids. Two residues (D-2-Nal and D-Phe) are in the D configuration, which substantially reduces susceptibility to common proteases.
• C-terminal amidation. The lysine C-terminus is amidated rather than free, another modification associated with increased metabolic stability in peptide chemistry.

Raun and colleagues at Novo Nordisk described ipamorelin in European Journal of Endocrinology in 1998. It emerged from a medicinal chemistry program built around growth hormone-releasing peptide-1 (GHRP-1); the authors identified it within a series of compounds that lacked the central Ala-Trp dipeptide of GHRP-1. A related program subsequently produced hybrid and orally directed analogues, including NN703.

Mechanism: GHS-R1a agonism

Ipamorelin is an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the G protein-coupled receptor cloned by Howard and colleagues in 1996 and localized to the pituitary and hypothalamus. The endogenous ligand for that receptor, the acylated stomach-derived peptide ghrelin, was identified three years later by Kojima and colleagues. Compounds acting at this receptor are therefore commonly described in the literature as ghrelin mimetics.

GHS-R1a signals principally through G_q and phospholipase C, producing inositol trisphosphate generation and intracellular calcium mobilization in somatotrophs. The functional consequence reported across the GHS class is a pulse of growth hormone release. This pathway is pharmacologically distinct from the GHRH receptor, which signals through G_s and cAMP; the two act on the same cell population but through separate receptors, which is why GHRH analogues and ghrelin mimetics are studied as mechanistically complementary rather than redundant.

In the original characterization, ipamorelin released GH from primary rat pituitary cells with potency and efficacy similar to GHRP-6. Pharmacological profiling with GHRP and GHRH antagonists indicated that the effect was mediated through a GHRP-like receptor rather than the GHRH receptor. Comparable GH-releasing activity was observed in anesthetized rats and in conscious swine.

The selectivity finding

The distinguishing observation in Raun et al. 1998 — and the reason ipamorelin is described in the literature as "the first selective growth hormone secretagogue" — concerns what it did not do. In the swine model, none of the secretagogues tested altered plasma FSH, LH, prolactin, or TSH. However, both GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, while ipamorelin did not release ACTH or cortisol at levels significantly different from those observed after GHRH stimulation. The authors noted that this held even at doses far above the ED₅₀ for GH release.

Two qualifications are worth stating plainly. First, this is a finding in swine, not a human endocrine study; it has been repeated extensively in secondary literature but the primary head-to-head data are preclinical. Second, "selective" here refers to a comparative hormone-release profile within a single set of experiments, not to receptor binding selectivity in the usual sense.

Pharmacokinetics reported in the literature

Gobburu and colleagues published a pharmacokinetic-pharmacodynamic analysis in healthy male volunteers in Pharmaceutical Research in 1999, using a dose-escalation design with short intravenous infusions. The reported parameters were dose-proportional, with a terminal half-life of approximately 2 hours, clearance of roughly 0.078 L/h/kg, and a steady-state volume of distribution near 0.22 L/kg. The GH response was characterized as a single release episode peaking at about 0.67 hours after administration and declining exponentially thereafter.

These are measured pharmacokinetic properties of the molecule as reported in that study. They are stated here as physical chemistry and disposition data, not as a basis for any use.

What the research has examined

Skeletal endpoints in rodents. Johansen and colleagues (1999) reported dose-dependent increases in longitudinal bone growth in rats. Svensson and colleagues (2000) reported that continuous administration of ipamorelin or GHRP-6 over twelve weeks increased bone mineral content measured by DXA in adult female rats. Andersen and colleagues (2001) examined ipamorelin against glucocorticoid-induced changes in adult rats and reported increased periosteal bone formation rate in the combination group relative to glucocorticoid alone.

Gastrointestinal motility. Because GHS-R1a activation has prokinetic effects, ipamorelin was investigated in rodent models of postoperative ileus by Venkova and colleagues (2009) and Greenwood-Van Meerveld and colleagues (2012), both reporting effects on gastric and intestinal transit.

Clinical work. That preclinical program led to the only substantial clinical study of the compound. Beck, Sweeney, McCarter and the Ipamorelin 201 Study Group published a phase 2, multicenter, randomized, double-blind, placebo-controlled proof-of-concept trial in International Journal of Colorectal Disease in 2014, in 117 adults undergoing small or large bowel resection. Intravenous ipamorelin was compared with placebo over up to seven postoperative days. Median time to first tolerated solid meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p = 0.15). The authors reported the regimen as well tolerated but found no significant difference between groups on the key or secondary efficacy endpoints. Development for that indication was discontinued.

Other reported effects. Adeghate and Ponery (2004) examined ipamorelin-evoked insulin release from pancreatic tissue of normal and diabetic rats, indicating activity outside the pituitary. More recently, Lu and colleagues (2024) reported that the GHS-R1a agonists anamorelin and ipamorelin inhibited cisplatin-induced weight loss in ferrets, a model relevant to cachexia research.

Comparison context within the GHS class

Ipamorelin is usually positioned in reviews against several other secretagogues. The following is descriptive, not a ranking:

• GHRP-6 and GHRP-2. Earlier GHRPs acting at the same receptor. In the 1998 swine comparison, GHRP-2 was more potent but less efficacious than ipamorelin for GH release, and both GHRP-6 and GHRP-2 raised ACTH and cortisol where ipamorelin did not. GHRP-6 is additionally associated with appetite-related signaling in the literature.
• Hexarelin. A hexapeptide GHS reported in reviews to have relatively pronounced effects on ACTH and cortisol, and to show desensitization of the GH response with continued exposure in study settings.
• CJC-1295. Mechanistically different — a long-acting GHRH analogue acting at the GHRH receptor, not GHS-R1a. Teichman and colleagues (2006) reported an estimated half-life of 5.8 to 8.1 days and sustained elevations of GH and IGF-I in healthy adults, a very different kinetic profile from the roughly 2-hour half-life reported for ipamorelin.
• Anamorelin, macimorelin, ibutamoren. Later GHS-R1a agonists, some orally active, developed for cachexia or as diagnostic agents. These have progressed further in formal regulatory pathways than ipamorelin did.

Handling and stability in a laboratory context

Ipamorelin is typically supplied as a lyophilized (freeze-dried) powder, often as the acetate or diacetate salt. General peptide-handling principles reported in the pharmaceutical literature apply to it:

• Lyophilized peptide powders are substantially more stable than aqueous solutions, and are normally stored cold, sealed, protected from light, and protected from atmospheric moisture, since residual water accelerates degradation.
• Once a peptide is in solution, the relevant degradation pathways include hydrolysis, oxidation of susceptible residues, deamidation, and aggregation or adsorption to container surfaces. Solution stability is generally shorter than solid-state stability and is temperature-dependent.
• Repeated freeze-thaw cycling is a recognized source of peptide degradation and aggregation in laboratory handling.
• Ipamorelin's D-amino acid substitutions and C-terminal amide confer resistance to enzymatic cleavage, but confer no protection against chemical degradation in solution.

These are general physicochemical properties of the compound class. Nothing here constitutes preparation, dilution, or administration instruction.

Limitations of the evidence

The honest summary of the ipamorelin literature is that it is thin on the human side and dated on the preclinical side.

• The human dataset is small. Ipamorelin has one published pharmacokinetic study in healthy volunteers and one published phase 2 efficacy trial. That trial did not meet its primary endpoint.
• The selectivity claim rests largely on one animal study. The ACTH and cortisol comparison that defines the compound's reputation comes from the 1998 swine experiments. It has not been extensively replicated in controlled human endocrine studies.
• No long-term data exist. Published exposure is short. There are no long-duration human safety datasets, and no data on chronic GHS-R1a agonism in humans with this molecule.
• Downstream endpoints are largely rodent endpoints. Bone mineral content, longitudinal growth, and body composition findings are from rat models, mostly published between 1999 and 2001.
• No approved indication. Ipamorelin is not an approved drug. Development by its originator and by subsequent licensees was discontinued. It is also listed among growth hormone secretagogues and ghrelin mimetics prohibited at all times under section S2 of the World Anti-Doping Agency Prohibited List.

Analytical methods for detecting ipamorelin and related GHRPs and their metabolites in human urine have been published in the anti-doping literature, for example by Semenistaya and colleagues (2015).

Closing note

Ipamorelin is best understood as a well-characterized pharmacological probe of the GHS-R1a pathway with a specific and historically important selectivity profile, and a clinical development record that stopped short of demonstrating efficacy for the indication it was tested in. Much of the material written about it elsewhere extrapolates well beyond that evidence base.

This article is reference material for research contexts. It is not medical advice, it is not a protocol, and it describes no human use. Compounds discussed here are research chemicals intended for laboratory investigation only and are not for human or veterinary administration.

References

• Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. PMID: 9849822. doi:10.1530/eje.0.1390552
• Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412–1416. doi:10.1023/A:1018955126402
• Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977. PMID: 8688086. doi:10.1126/science.273.5277.974
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. PMID: 10604470. doi:10.1038/45230
• Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Ørskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106–113. PMID: 10373343. doi:10.1054/ghir.1999.9998
• Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000;165(3):569–577.
• Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research. 2001;11(5):266–272. PMID: 11735244. doi:10.1054/ghir.2001.0239
• Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics. 2009;329(3):1110–1116. PMID: 19289567. doi:10.1124/jpet.108.149211
• Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology. 2012;4:149–155. PMID: 27186127. doi:10.2147/JEP.S35396
• Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527–1534. PMID: 25331030. doi:10.1007/s00384-014-2030-8
• Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters. 2004;25(6):403–406. PMID: 15665799
• Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. 2024;284:114644. PMID: 39043357. doi:10.1016/j.physbeh.2024.114644
• Hansen TK, Ankersen M, Raun K, Hansen BS. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorganic & Medicinal Chemistry Letters. 2001;11(14):1915–1918. PMID: 11459660. doi:10.1016/S0960-894X(01)00345-6
• Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. PMID: 16352683
• Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Testing and Analysis. 2015;7(10):919–925. PMID: 25869809. doi:10.1002/dta.1787
• Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Frontiers in Endocrinology. 2026;17:1822475. PMID: 42395176. doi:10.3389/fendo.2026.1822475
• World Anti-Doping Agency. The Prohibited List, section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). wada-ama.org/en/prohibited-list